Evidence map›Paper›PMID 41900625›Full record

ReviewMaterials (Basel, Switzerland)2026

Concentration-Dependent Anticancer Effects of Melittin-Functionalized Nanomaterials.

Alex Câmpian, Adrian Florea

Abstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. In Vitro Antitumor Effects of Melittin Attached to FeMolecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alex CâmpianDepartment of Cell and Molecular Biology, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 6 Louis Pasteur St., 400349 Cluj-Napoca, Romania.
Adrian FloreaDepartment of Cell and Molecular Biology, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 6 Louis Pasteur St., 400349 Cluj-Napoca, Romania.ORCID 0000-0002-0898-7626

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melittin-functionalized nanoparticles have emerged as a strategy to harness the potent anticancer activity of melittin while mitigating its narrow therapeutic window. Across diverse nanocarrier platforms, biological outcomes are highly dependent on the effective melittin concentration presented to tumour cells. This review systematically examines concentration-dependent anticancer effects of melittin-functionalized nanoparticles, focusing on quantitative dose-response metrics such as IC

Indexed as

apoptosiscancerdose–responsemelittinnanomaterialsnecrosis

Identifiers

PMID41900625
PMCPMC13027721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.